Ultragenyx Announces Submission of New Drug Application to FDA for UX007 (triheptanoin) for Treatment of Long-Chain Fatty Acid Oxidation Disorders
Go back to Ultragenyx Announces Submission of New Drug Application to FDA for UX007 (triheptanoin) for Treatment of Long-Chain Fatty Acid Oxidation Disorders| ULTRAGENYX PHARM (NASDAQ: RARE) | Delayed: 29.88 +0.77 (2.65%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $29.11 | 52 Week High | $117.12 | |||
| Open | $29.51 | 52 Week Low | $46.52 | |||
| Day High | $30.57 | P/E | N/A | |||
| Day Low | $29.33 | EPS | $-1.97 | |||
| Volume | 824,595 | |||||
